secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-124581
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology reports Q3 2024 net loss of $21.2M; cash runway into 2H 2026
---------------------------------------------------------------------------

- Cash and equivalents of $146.3M as of Sept 30, 2024; expected to fund operations into 2H 2026.
- Net loss of $21.2M ($0.35/share) vs $23.0M ($0.56/share) in Q3 2023.
- R&D expenses rose to $17.7M from $14.7M due to increased clinical trial costs for PYX-201 and PYX-106.
- Preliminary Phase 1 data for lead ADC PYX-201 to be presented at investor event on Nov 20, 2024; 80 patients dosed.
- Phase 1 data for PYX-106 (Siglec-15 antibody) expected by year-end 2024; 45 patients dosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017024124581/0000950170-24-124581-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017024124581/pyxs-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-124581

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer